Grants and Contributions:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

A promising approach to drug formulation is the design of cocrystals to improve the physicochemicalx000D
properties of active pharmaceutical ingredients (APIs), while maintaining its therapeutic activity. Cocrystalsx000D
have the ability to alter certain API characteristics, such as solubility, dissolution, and stability that play a majorx000D
role in overcoming problems associated with drug delivery and bioavailability. However, current approachesx000D
for designing API co-crystals, rely on the use of time-consuming and expensive experimental based co-crystalx000D
screens.x000D
To overcome these limitations, Apotex Pharmachem, Canada's largest developer and manufacturer of genericx000D
pharmaceuticals seeks to develop high-throughput (HT) screening approaches for designing API co-crystals. Inx000D
collaboration with Brock University, the proposed research aims to develop a novel computer-based approachx000D
to co-crystal design by using a combination of statistical and quantum mechanical modelling methods. Thesex000D
project outcomes will be the first step towards accelerating the formulation development process and allow forx000D
the reliable prediction of API co-crystal stability. This has wide ranging implications for Apotex to generatex000D
innovative pharmaceuticals and various dosage forms, thus further establishing Canada's place as global leaderx000D
in science, innovation, and technology.